Opinion|Videos|July 12, 2024
PERSEUS Trial Findings at EHA 2024
Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on minimal residual disease (MRD) in the PERSEUS trial of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by daratumumab/lenalidomide (D-R) in patients with newly diagnosed multiple myeloma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with multiple myeloma?
- How have the criteria for multiple myeloma patients to be considered transplant-eligible or -ineligible evolved in recent history? How do you evaluate transplant eligibility in your practice?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5